What is OnKure Therapeutics's earnings per share (EPS)?

OnKure Therapeutics (OKUR) reported diluted earnings per share of $-4.40 for fiscal year 2025. This represents a 71.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

OnKure Therapeutics Financials

OKUR

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows OnKure Therapeutics (OKUR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OKUR FY2025 2026-05-05

OnKure operates as a cash-funded R&D platform where financing resets, not sales, do most of the balance-sheet shaping.

Between FY2023 and FY2024, cash jumped from $29.9M to $110.8M while total liabilities collapsed from $137.6M to $11.1M, effectively resetting a balance sheet that had been carrying negative equity. In FY2025, with financing cash flow only $163K, the -$51.9M free-cash outflow was absorbed almost entirely by that prior cash build, showing the company is now operating off money already raised rather than fresh annual funding.

The near-match between operating cash flow of -$51.8M and free cash flow of -$51.9M in FY2025, with capex only $46K, says the burn comes from day-to-day operations rather than asset building. That means cash use is structural to the current research model, not a temporary consequence of heavy capital investment.

R&D remained the dominant spend at $48.3M versus SG&A of $14.7M in FY2025, which fits a business still funding development rather than commercialization. Liquidity is comfortable near term because cash was $59.1M against current liabilities of $5.9M, but that cash balance is only modestly larger than one recent year of burn.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of OnKure Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

OnKure Therapeutics carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 10.28, OnKure Therapeutics holds $10.28 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

OnKure Therapeutics generates a -105.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -50.7% the prior year.

Piotroski F-Score Weak

1/9

OnKure Therapeutics passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.87x

For every $1 of reported earnings, OnKure Therapeutics generates $0.87 in operating cash flow (-$51.8M OCF vs -$59.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-18.3x

OnKure Therapeutics earns $-18.3 in operating income for every $1 of interest expense (-$63.0M vs $3.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$62.5M

YoY-15.9%

OnKure Therapeutics's EBITDA was -$62.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 15.9% from the prior year.

Net Income

-$59.5M

YoY-13.0%

OnKure Therapeutics reported -$59.5M in net income in fiscal year 2025. This represents a decrease of 13.0% from the prior year.

EPS (Diluted)

$-4.40

YoY+71.2%

OnKure Therapeutics earned $-4.40 per diluted share (EPS) in fiscal year 2025. This represents an increase of 71.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$51.9M

YoY-1.4%

OnKure Therapeutics generated -$51.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.4% from the prior year.

Cash & Debt

$59.0M

YoY-46.7%

5Y CAGR+2.0%

OnKure Therapeutics held $59.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-105.9%

YoY-55.2pp

OnKure Therapeutics's ROE was -105.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 55.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$48.3M

YoY+10.2%

5Y CAGR+24.8%

OnKure Therapeutics invested $48.3M in research and development in fiscal year 2025. This represents an increase of 10.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$46K

YoY-11.5%

5Y CAGR+13.9%

OnKure Therapeutics invested $46K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.5% from the prior year.

OKUR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$0	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$48.3M+10.2%	$43.8M+36.4%	$32.1M-14.8%	$37.7M+33.9%	$28.2M+76.7%	$15.9M
SG&A Expenses	$14.7M+38.7%	$10.6M+119.8%	$4.8M-70.1%	$16.1M+38.6%	$11.6M+222.9%	$3.6M
Operating Income	-$63.0M-15.7%	-$54.4M-47.3%	-$36.9M+31.4%	-$53.8M-35.2%	-$39.8M-103.7%	-$19.6M
Interest Expense	$3.4M+100.4%	$1.7M+5.5%	$1.6M	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$59.5M-13.0%	-$52.7M-49.2%	-$35.3M+32.0%	-$52.0M-30.6%	-$39.8M-104.3%	-$19.5M
EPS (Diluted)	$-4.40+71.2%	$-15.28+87.7%	$-124.41	$-2.12+3.2%	$-2.19	$-9.60

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.7M	N/A	$11.9M-5.5%	$12.6M-3.1%	$13.0M	N/A	$10.1M-5.9%	$10.8M
SG&A Expenses	$3.9M	N/A	$3.6M-3.4%	$3.7M-6.9%	$4.0M	N/A	$1.4M-61.1%	$3.6M
Operating Income	-$15.6M	N/A	-$15.5M+5.0%	-$16.3M+4.0%	-$17.0M	N/A	-$11.5M+19.7%	-$14.3M
Interest Expense	$458K	N/A	$802K-14.1%	$934K-13.1%	$1.1M	N/A	-$44K-121.6%	$204K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$15.2M-12.2%	-$13.5M+8.1%	-$14.7M+4.5%	-$15.4M+3.4%	-$15.9M+8.7%	-$17.4M-50.9%	-$11.6M+18.3%	-$14.1M
EPS (Diluted)	$-1.11	N/A	$-1.09+4.4%	$-1.14+4.2%	$-1.19	N/A	$-36.55	$-44.82

OKUR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$62.1M-45.9%	$114.9M+221.6%	$35.7M-67.0%	$108.2M-29.8%	$154.0M+178.9%	$55.2M
Current Assets	$60.8M-46.2%	$113.0M+234.7%	$33.8M-68.3%	$106.4M-30.8%	$153.7M+179.4%	$55.0M
Cash & Equivalents	$59.0M-46.7%	$110.8M+270.7%	$29.9M+49.9%	$19.9M-84.0%	$124.7M+132.5%	$53.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.9M-46.4%	$11.1M-91.9%	$137.6M-15.4%	$162.6M+2286.6%	$6.8M-93.0%	$97.3M
Current Liabilities	$5.9M-43.8%	$10.5M+44.5%	$7.3M+2.3%	$7.1M+14.9%	$6.2M+35.4%	$4.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$56.2M-45.9%	$103.8M+202.0%	-$101.8M-87.1%	-$54.4M-137.0%	$147.2M+449.5%	-$42.1M
Retained Earnings	-$214.2M-38.5%	-$154.7M-51.6%	-$102.1M+25.3%	-$136.7M-61.3%	-$84.7M-88.5%	-$45.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$198.7M+219.9%	$62.1M-14.7%	$72.8M-15.4%	$86.1M-13.8%	$99.9M-13.1%	$114.9M+48.0%	$77.6M-1.4%	$78.7M
Current Assets	$197.5M+224.6%	$60.8M-14.9%	$71.5M-15.4%	$84.6M-13.9%	$98.2M-13.1%	$113.0M+46.8%	$77.0M-1.3%	$78.0M
Cash & Equivalents	$192.1M+225.3%	$59.0M-16.0%	$70.3M-15.6%	$83.4M-13.7%	$96.7M-12.7%	$110.8M+82.5%	$60.7M+68.7%	$36.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.3M+141.7%	$5.9M-7.4%	$6.4M-18.9%	$7.9M-14.4%	$9.2M-16.7%	$11.1M-94.8%	$212.7M+5.1%	$202.3M
Current Liabilities	$14.3M+142.0%	$5.9M-5.2%	$6.2M-17.8%	$7.6M-13.5%	$8.8M-16.6%	$10.5M+224.2%	$3.2M+140.9%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$184.4M+228.1%	$56.2M-15.4%	$66.4M-15.0%	$78.2M-13.8%	$90.6M-12.7%	$103.8M+176.9%	-$135.1M-9.3%	-$123.6M
Retained Earnings	-$229.4M-7.1%	-$214.2M-6.7%	-$200.7M-7.9%	-$186.0M-9.0%	-$170.6M-10.3%	-$154.7M+34.4%	-$236.0M-1.6%	-$232.3M

OKUR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$51.8M-1.4%	-$51.1M-48.0%	-$34.5M+27.1%	-$47.4M-24.7%	-$38.0M-104.9%	-$18.5M
Capital Expenditures	$46K-11.5%	$52K-78.9%	$246K-28.9%	$346K+74.7%	$198K+725.0%	$24K
Free Cash Flow	-$51.9M-1.4%	-$51.2M-47.1%	-$34.8M+27.1%	-$47.7M-25.0%	-$38.2M-105.7%	-$18.6M
Investing Cash Flow	-$46K-100.3%	$15.9M+6552.4%	-$246K+99.6%	-$57.8M-147.4%	-$23.4M-416.9%	$7.4M
Financing Cash Flow	$163K-99.9%	$116.1M+118.6%	$53.1M+11179.2%	$471K-99.6%	$132.4M+180.1%	$47.3M
Dividends Paid	N/A	$0	$0	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$4.4M	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$12.9M-12.4%	-$11.5M+11.7%	-$13.0M+1.8%	-$13.3M+5.2%	-$14.0M+40.0%	-$23.4M-119.1%	-$10.7M-64.7%	-$6.5M
Capital Expenditures	$5K-44.4%	$9K+50.0%	$6K-53.8%	$13K-27.8%	$18K+20.0%	$15K-16.7%	$18K+80.0%	$10K
Free Cash Flow	-$12.9M-12.3%	-$11.5M+11.7%	-$13.0M+1.8%	-$13.3M+5.2%	-$14.0M+40.0%	-$23.4M-118.8%	-$10.7M-64.7%	-$6.5M
Investing Cash Flow	-$5K+44.4%	-$9K-50.0%	-$6K+53.8%	-$13K+27.8%	-$18K-100.1%	$15.9M+88488.9%	-$18K-80.0%	-$10K
Financing Cash Flow	$146.0M+60732.9%	$240K	$0	$0+100.0%	-$77K-100.1%	$110.2M+2204820.0%	$5K-99.9%	$5.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OKUR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-105.9%-55.2pp	-50.7%	N/A	N/A	-27.0%	N/A
Return on Assets	-95.8%-50.0pp	-45.8%+53.0pp	-98.8%-50.8pp	-48.0%-22.2pp	-25.8%+9.4pp	-35.3%
Current Ratio	10.28-0.5	10.73+6.1	4.63-10.3	14.93-9.9	24.79+12.8	12.01
Debt-to-Equity	0.110.0	0.11+1.5	-1.35+1.6	-2.99-3.0	0.05+2.4	-2.31
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-8.2%+15.8pp	-24.0%-1.9pp	-22.1%-2.4pp	-19.7%-2.1pp	-17.6%-0.8pp	-16.8%	N/A	N/A
Return on Assets	-7.6%+14.1pp	-21.7%-1.6pp	-20.2%-2.3pp	-17.9%-1.9pp	-15.9%-0.8pp	-15.2%-0.3pp	-14.9%+3.1pp	-18.0%
Current Ratio	13.78+3.5	10.28-1.2	11.45+0.3	11.13-0.0	11.18+0.4	10.73-13.0	23.71-34.1	57.86
Debt-to-Equity	0.08-0.0	0.110.0	0.100.0	0.100.0	0.100.0	0.11+1.7	-1.57+0.1	-1.64
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

AN2 Therapeutics, Inc. ANTX

$165.3M

Estrella Immunopharma ESLA

$49.1M

Frequently Asked Questions

Is OnKure Therapeutics profitable?

No, OnKure Therapeutics (OKUR) reported a net income of -$59.5M in fiscal year 2025.

What is OnKure Therapeutics's EBITDA?

OnKure Therapeutics (OKUR) had EBITDA of -$62.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is OnKure Therapeutics's return on equity (ROE)?

OnKure Therapeutics (OKUR) has a return on equity of -105.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is OnKure Therapeutics's free cash flow?

OnKure Therapeutics (OKUR) generated -$51.9M in free cash flow during fiscal year 2025. This represents a -1.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is OnKure Therapeutics's operating cash flow?

OnKure Therapeutics (OKUR) generated -$51.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are OnKure Therapeutics's total assets?

OnKure Therapeutics (OKUR) had $62.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are OnKure Therapeutics's capital expenditures?

OnKure Therapeutics (OKUR) invested $46K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does OnKure Therapeutics spend on research and development?

OnKure Therapeutics (OKUR) invested $48.3M in research and development during fiscal year 2025.

What is OnKure Therapeutics's current ratio?

OnKure Therapeutics (OKUR) had a current ratio of 10.28 as of fiscal year 2025, which is generally considered healthy.

What is OnKure Therapeutics's debt-to-equity ratio?

OnKure Therapeutics (OKUR) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is OnKure Therapeutics's return on assets (ROA)?

OnKure Therapeutics (OKUR) had a return on assets of -95.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is OnKure Therapeutics's cash runway?

Based on fiscal year 2025 data, OnKure Therapeutics (OKUR) had $59.0M in cash against an annual operating cash burn of $51.8M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is OnKure Therapeutics's Piotroski F-Score?

OnKure Therapeutics (OKUR) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are OnKure Therapeutics's earnings high quality?

OnKure Therapeutics (OKUR) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can OnKure Therapeutics cover its interest payments?

OnKure Therapeutics (OKUR) has an interest coverage ratio of -18.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is OnKure Therapeutics?

OnKure Therapeutics (OKUR) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.